Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2005

View Archived Issues

New mode of cell death achieved with novel CDK4 homologous peptide

Targeting urotensin II for CHF and restenosis following balloon angioplasty

Apoptosis-inducing metal-based complexes described by Irish scientists

Allergy Therapeutics updates status of allergy vaccine programs

Senexis and Galapagos expand collaboration

Idenix outlines plans for valopicitabine phase III trials

Positive results disclosed from MEND-CABG study of MC-1

FDA gives feedback on phase III study protocol for cethromycin in CAP

Cel-Sci signs cooperative agreement with NIAID to test CEL-1000 for bird flu

Study to investigate Phytosel's ability to lower chemotherapy side effects

UGT1A1 test launched to determine appropriate Camptosar dosage

VX-950 enters phase II development for HCV

Neuren raises funding to advance neurological compounds

Merck submits Gardasil BLA

Hylenex receives FDA approval

PXD-101: update on cancer studies

Phenoxodiol effective for malignant SCC of the cervix, vagina or vulva and advanced prostate cancer

Targeting Tie-1 for cancer

A benzodiazepine modulates c-myc

Targeting tissue factor enhances paclitaxel activity

Data on human monoclonal antibodies to TRAIL receptors

Preclinical studies show curcumin prevents breast cancer metastasis

New therapeutics for cancer disclosed in recent patents

Novel agents for alopecia, psoriasis claimed in recent patents

DailyDrugNews.com invites users to participate in Reader Survey

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...